Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.49 |
| ▸ | PRKACA | P17612 | 3/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | AHCY | P23526 | 1/20 | 0.41 |
| ▸ | QARS1 | P47897 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540124 | 0.90 | DOT1L (0.61) | DOT1LPRKACAPRMT1NNMTAHCY | |
| SCHEMBL29540296 | 0.81 | KLK7 (0.42) | DOT1LPRKACAROCK2 | |
| SCHEMBL16288362 | 0.77 | RNASEL (0.42) | DOT1L | |
| SCHEMBL16288361 | 0.77 | RNASEL (0.42) | DOT1L | |
| SCHEMBL16288376 | 0.77 | RNASEL (0.42) | DOT1L | |
| SCHEMBL16288372 | 0.77 | RNASEL (0.42) | DOT1L | |
| SCHEMBL16288365 | 0.77 | RNASEL (0.42) | DOT1L | |
| SCHEMBL15083478 | 0.77 | RNASEL (0.42) | DOT1L | |
| SCHEMBL16310602 | 0.77 | RNASEL (0.42) | DOT1L | |
| SCHEMBL23056438 | 0.77 | DOT1L (0.43) | DOT1LPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | DOT1L 4554/4885PRKACA 987/4885PRMT1 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.